title: Fasudil inhibits tissue factor and plasminogen activator Inhibitor-1 secretion by peripheral blood mononuclear cells in CAPD patients.
abstract: Disturbances in hemostasis are common complications of kidney diseases and correlate well with cardiovascular mortality. Little is known about the effects of fasudil on tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) expression in peripheral blood mononuclear cells (PBMCs) in CAPD patients. PBMCs were isolated from 13 individuals with CAPD and 13 healthy subjects. After 4 h of incubation with or without LPS (10 ng/mL), TF and PAI-1 mRNA of PBMCs were detected by RT-PCR. The levels of TF and PAI-1 in culture supernatants of PBMCs were determined by ELISA. Compared with healthy controls, CAPD patients had increased TF, PAI-1 protein and mRNA expression by PBMCs at baseline and after stimulated by LPS (10 ng/mL) [p < 0.001]. The fasudil treatment resulted in a significant effect in decreasing TF and PAI-1 [p < 0.05] synthesis in PBMCs. TF and PAI-1 mRNA expression and activities in PBMCs were increased in CAPD patients. Fasudil reduced LPS-mediated TF and PAI-1 expression and activity in PBMCs. These effects may partially be relevant to the clinical benefits of fasudil in the treatment of CAPD patients.
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Wenning
authors.initials: W
authors.lastname: Li
authors.affiliation: b Department of Nephrology , the Second Affiliated Hospital of Hainan Medical College , Haikou , Hainan , China.
authors.forename: Wen
authors.initials: W
authors.lastname: Chen
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Maowei
authors.initials: M
authors.lastname: Xie
authors.affiliation: c Central Laboratory , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Huang
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Huiluan
authors.initials: H
authors.lastname: Su
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Hui
authors.initials: H
authors.lastname: Han
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Daofa
authors.initials: D
authors.lastname: Zhang
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Yang
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Wentan
authors.initials: W
authors.lastname: Xu
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Su
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Huang
authors.affiliation: c Central Laboratory , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Keying
authors.initials: K
authors.lastname: Fu
authors.affiliation: a Department of Nephrology , Hainan General Hospital , Haikou , Hainan , China.
authors.forename: Jiali
authors.initials: J
authors.lastname: Wei
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D005786:Gene Expression Regulation; D006801:Humans; D007676:Kidney Failure, Chronic / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013925:Thromboplastin / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D013925:Thromboplastin; C049347:fasudil
keywords: Fasudil; continuous ambulatory peritoneal dialysis; peripheral blood mononuclear cells; plasminogen activator inhibitor-1; tissue factor